Dual-Directional Immunomodulatory Effects of Corbrin Capsule on Autoimmune Thyroid Diseases
Table 4
Baseline and end of treatment of subjects in Hashimoto’s thyroiditis.
HT-Tx
HT-Ct
Baseline
End of treatment
value
Baseline
End of treatment
value
FT3 (pmol/L)
3.39 1.01
4.19 1.03
0.469
3.42 1.12
3.92 1.30
0.754
FT4 (pmol/L)
11.83 3.64
14.91 2.14
0.002
10.47 3.59
14.33 1.78
0.003
TSH (IU/L)
10.94 6.52
3.36 1.19
0.003
9.75 7.21
3.09 2.07
0.031
TPO-Ab (IU/mL)
820.51 572.4
454.05 227.96
0.022
829.39 388.29
717.19 213.63
0.217
TG-Ab (IU/mL)
547.8 331.45
331.45 124.61
0.037
593.28 273.65
561.82 196.97
0.603
CD3+ (%)
69.56 8.57
64.12 8.18
0.051
67.62 8.36
68.11 2.55
0.838
CD4+ (%)
34.47 6.74
36.77 4.32
0.791
33.96 4.29
34.00 2.19
0.962
CD8+ (%)
29.07 7.06
23.92 6.20
0.031
28.98 6.54
25.91 3.17
0.295
CD4/CD8 ratio
1.23 0.55
1.51 0.46
0.024
1.19 0.68
1.33 0.21
0.457
The data of HT-Tx group and HT-Ct group were compared between the start and end of treatment (24 weeks). In the HT-Tx group, there were an increase of CD4+, a significant decrease of CD8+, and an increased CD4/CD8 ratio compared to the baseline. None of the parameters changed significantly in HT-Ct group.
